Hilliard Lyons Upgrades Abbott Labs (ABT) to Buy
More News related to ABT
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- The Deal Names Abbott Top Dealmaker for Second Consecutive Year
- Hilliard Lyons Downgrades Abbott Labs (ABT) to Long-Term Buy
- Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics Platform
- Morgan Joseph Initiates Coverage on Boston Scientific (BSX) with a Hold; Shares Fully Valued
Hilliard Lyons upgrades Abbott Labs (NYSE: ABT) from Long-Term Buy to Buy.
Shares of Abbott are trading relatively flat from yesterday's close, currently up just 0.2% to $44.42.
To see all the analyst upgrades/downgrades on shares of Abbott, visit our Analyst Ratings page.
Abbott Laboratories manufactures and sells health care products worldwide.
Related Categories
UpgradesStocks Mentioned
-0.33Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
